AngioSoma (NASDAQ:SOAN) major shareholder Brent Atwood acquired 12,176,719 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was acquired at an average cost of $0.02 per share, for a total transaction of $243,534.38. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

SOAN stock opened at $0.01 on Monday. AngioSoma has a 12 month low of $0.00 and a 12 month high of $0.06.

AngioSoma Company Profile

AngioSoma, Inc operates as a clinical stage biotechnology company. The company's lead drug candidates include Liprostin that completed Phase I and three Phase II clinical trials, and Prostaglandin E1 that completed Phase II clinical trials for the treatment of peripheral artery diseases. It also markets a line of nutraceutical supplements under the SomaCeuticals name.

Featured Story: How to Use the New Google Finance Tool

Receive News & Ratings for AngioSoma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioSoma and related companies with's FREE daily email newsletter.